Article
Pathology
Yoon Ah Cho, Jiyeon Hyeon, Hyunwoo Lee, Junhun Cho, Seok-Jin Kim, Won Seog Kim, Young-Hyeh Ko
Summary: MYC-rearranged large B-cell lymphoma with BCL2 and/or BCL6 rearrangement, double-hit or triple-hit lymphoma, is associated with poor survival. In contrast, single-hit MYC rearrangement showed high-grade morphology but similar survival rates to MYC-negative lymphomas.
Article
Hematology
Waleed Alduaij, Brett Collinge, Susana Ben-Neriah, Aixiang Jiang, Laura K. Hilton, Merrill Boyle, Barbara Meissner, Lauren Chong, Tomoko Miyata-Takata, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Andrew Lytle, Kerry J. Savage, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Randy D. Gascoyne, Joseph M. Connors, Ryan D. Morin, Laurie H. Sehn, Andrew J. Mungall, Christian Steidl, David W. Scott
Summary: This study found that the molecular heterogeneity of DLBCL leads to variable outcomes with immunochemotherapy. DZsig expression extends beyond HGBCL-DH-BCL2 and captures a poor-prognosis DLBCL subgroup with short DTI, including patients unidentifiable by routine FISH testing, that should be considered for treatment intensification or novel therapies in prospective trials.
Review
Hematology
Kerry J. Savage
Summary: This article discusses the unique features of PMBCL and the choice of treatment options. Accurate diagnosis can be made based on clinical information and molecular classifiers, and emerging data suggest the high efficacy of PD1 inhibitors in PMBCL treatment.
Article
Genetics & Heredity
Yanan Jiang, Huimeng Sun, Hong Xu, Xin Hu, Wenqi Wu, Yangyang Lv, Jinhuan Wang, Su Liu, Yixin Zhai, Linyan Tian, Yafei Wang, Zhigang Zhao
Summary: A study on DLBCL revealed two immune infiltration subtypes and developed a 16-gene risk signature for prognostic prediction. The high-risk group showed lower immune infiltration, more aggressive phenotypes, lower overall survival, and greater sensitivity to lenalidomide, while the low-risk group showed higher immune infiltration, less aggressive phenotypes, better overall survival, and a higher likelihood of benefiting from PD-1/PD-L1 inhibitors.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Masashi Miyaoka, Yara Yukie Kikuti, Joaquim Carreras, Atsushi Ito, Haruka Ikoma, Sakura Tomita, Hiroshi Kawada, Giovanna Roncador, Silvia Bea, Elias Campo, Naoya Nakamura
Summary: This study analyzed different subtypes of DLBCL using various methods and found that they have distinct genetic features and gene mutations. These findings are important for the comprehensive understanding of the molecular mechanisms of DLBCL and for providing personalized treatment strategies.
Article
Oncology
Jessica Rodrigues Placa, Arjan Diepstra, Tjitske Los, Matias Mendeville, Annika Seitz, Pieternella J. Lugtenburg, Josee Zijlstra, King Lam, Wilson Araujo da Silva Jr, Bauke Ylstra, Daphne de Jong, Anke van den Berg, Marcel Nijland
Summary: This study reproduced four gene expression signatures in DLBCL patients and validated three of them. In addition to the cell of origin, other signatures related to immune response and MYC activity were identified. These signatures capture different aspects of DLBCL biology and can co-occur in the same patient.
Article
Immunology
Carmen Gomez-Escolar, Ester Marina-Zarate, Almudena R. Ramiro
Summary: Germinal centers are important for secondary antibody diversification and vaccination strategies. Activation-induced deaminase (AID) plays a crucial role in this process but can also cause genomic mutations and chromosome translocations with oncogenic potential. Many human lymphomas originate from mature B cells that have undergone germinal center reactions and carry chromosome translocations. Mouse models employing genetic introduction of chromosome translocations have contributed to the understanding of mature B cell lymphomagenesis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Anett Baliko, Zsolt Szakacs, Bela Kajtar, Zsombor Ritter, Attila Gyenesei, Nelli Farkas, Laszlo Kereskai, Istvan Valyi-Nagy, Hussain Alizadeh, Laszlo Pajor
Summary: This study evaluates the application of immunohistochemistry and FISH molecular markers in the diagnosis and prognosis of DLBCL. The results show that IPI, BCL6 protein expression, and MIB-1 protein expression are independent predictors of survival outcomes in DLBCL. There is no difference in survival between GCB and non-GCB subtypes. These findings may improve prognostication in DLBCL and contribute to further research.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pathology
Madeleine R. Berendsen, Diede A. G. van Bladel, Eva Hesius, Fleur A. de Groot, Leonie I. Kroeze, Jos Rijntjes, Jeroen A. C. W. Luijks, Brigiet Hoevenaars, Altuna Halilovic, Peet Nooijen, Esther van Bladel, Susan de Jonge-Peeters, Chantal Lensen, Hans Pruijt, Ellen van der Spek, Joost S. P. Vermaat, Corine Hess, Konnie M. Hebeda, Wendy B. C. Stevens, J. Han J. M. van Krieken, Michiel van den Brand, Patricia J. T. A. Groenen, Blanca Scheijen
Summary: This study established the clonal relationship between diagnoses and recurrences of diffuse large B-cell lymphoma (DLBCL) using next-generation sequencing-based detection. Among the 50 patients with interpretable results, 86% developed clonally related relapsed disease, while 14% displayed different dominant clonotypes, confirming the occurrence of second primary DLBCL. Late recurrences should consider next-generation sequencing-based clonality testing to distinguish relapse from second primary lymphoma.
Article
Pathology
Zaneta Swiderska-Chadaj, Konnie M. Hebeda, Michiel van den Brand, Geert Litjens
Summary: A deep learning algorithm was developed to detect MYC rearrangement in scanned histological slides, showing a high sensitivity of 0.93 and specificity of 0.52. This approach could allow for simple and fast prescreening, potentially saving around 34% of genetic tests.
Article
Oncology
Wei Qin, Di Fu, Qing Shi, Lei Dong, Hongmei Yi, Hengye Huang, Xufeng Jiang, Qi Song, Zhenhua Liu, Shu Cheng, Jinyan Huang, Li Wang, Pengpeng Xu, Weili Zhao
Summary: The clinical and molecular characteristics of localized diffuse large B-cell lymphoma with single nodal or single extranodal involvement in the rituximab era are complex and not fully understood. Analysis of clinical features, genetic aberrations, and tumor immunophenotype can guide personalized treatment for localized DLBCL in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Zi-qi Chen, Zhe-rui Cao, Yi Wang, Xi Zhang, Lan Xu, Yu-xiang Wang, Yi Chen, Chun-hao Yang, Jian Ding, Ling-hua Meng
Summary: This study revealed the importance of PI3Kα in B cell lymphoma cell proliferation, with the novel PI3Kα-selective inhibitor CYH33 showing superior activity against BCL compared to other inhibitors. Additionally, combination therapy of CYH33 with the BET inhibitor OTX015 was found to significantly enhance the treatment efficacy against BCL through inhibition of c-MYC expression and induction of cell cycle arrest and apoptosis, suggesting a promising therapeutic strategy.
Article
Cell Biology
Jessica Maguire, Harry Harvey, Alfred Jones, Ruth Law, Masoud Bashir, Odharnaith O'Brien, Jeremy Sargent, Cliona Grant, Richard Flavin
Summary: This study highlights the difficulties in classifying LBCL-IRF4 cases that arise in adult patients, particularly those with unusual clinical features.
Review
Oncology
Paola Chabay
Summary: EBV+ DLBCL, NOS is a new category with varying incidence rates among different populations, influencing tumor microenvironment and patient survival. EBV can alter genetic composition of tumor cells and affect recruitment of immune cells.
Article
Oncology
Yanjie Wang, Donglin Liu, Xudong Zhang, Mingzhi Zhang, Shenglei Li, Xiaoyan Feng, Meng Dong, Shanshan Ma, Siyu Qian, Zeyuan Wang, Yue Zhang, Pengyuan Wang, Shuhao Mei, Qingjiang Chen
Summary: The prognostic value of MYC protein expression and other biological parameters in bulky mass DLBCL patients were analyzed in this study. The results showed that MYC overexpression was associated with worse overall survival and progression-free survival, and consolidation radiotherapy improved outcomes for patients with bulky mass DLBCL.
